AI Article Synopsis
- Gallbladder cancer (GBC) is increasingly affecting young adults and is linked to 10 key modifiable risk factors, which account for about 75% of cases globally.
- The study found that central obesity, gallstones, and physical inactivity are the top contributors to GBC, particularly impacting women.
- Most cases are preventable, highlighting the importance of addressing metabolic health conditions to reduce the risk of GBC.
Article Abstract
Gallbladder cancer (GBC) is a highly lethal and often overlooked malignancy increasingly affecting young adults. This study quantified the global proportion of GBC cases attributable to 10 key modifiable risk factors, employing Monte Carlo simulations and estimates from field-wide systematic review and meta-analysis. Approximately three-quarters of global GBC cases are attributable to key modifiable factors (74.6%; 95% uncertainty interval, 63.7-83.7), with a slightly higher share observed in females. Central obesity (29.7%; 8.7-49.5), gallstones (27.9%; 16.8-40.7), and physical inactivity (20.5%; 7.4-34.1) were identified as the leading contributors. Most GBC cases are preventable, with a large share linked to metabolic health conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.18486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global Burden of Gallbladder Cancer Attributable to Modifiable Risk Factors.
Aliment Pharmacol Ther
January 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Article Synopsis
- Gallbladder cancer (GBC) is increasingly affecting young adults and is linked to 10 key modifiable risk factors, which account for about 75% of cases globally.
- The study found that central obesity, gallstones, and physical inactivity are the top contributors to GBC, particularly impacting women.
- Most cases are preventable, highlighting the importance of addressing metabolic health conditions to reduce the risk of GBC.
Frequency of Gallbladder Carcinoma in Patients Operated for Symptomatic Cholelithiasis.
Cureus
December 2024
Department of General Surgery, Fauji Foundation Hospital, Peshawar, PAK.
Background Gallbladder carcinoma (GBC) is a rare but highly aggressive malignancy, often discovered incidentally during cholecystectomy for symptomatic cholelithiasis. Despite significant geographic variation, the association between gallstones and GBC is well-documented, with chronic inflammation from gallstones potentially contributing to carcinogenesis. Objective This study aims to determine the prevalence of incidental GBC in patients undergoing cholecystectomy for symptomatic cholelithiasis at a tertiary care hospital in Peshawar, Pakistan.
View Article and Find Full Text PDFPropensity score analysis of adjuvant therapy in radically resected gallbladder cancers: a real world experience from a regional cancer center.
Ann Hepatobiliary Pancreat Surg
December 2024
Department of Biostatistics and Health Informatics, Sanjay Gandhi Post-graduate Institute of Medical Sciences, Lucknow, India.
Backgrounds/aims: Given the high mortality associated with gallbladder cancer (GBC), the efficacy of adjuvant therapy (AT) remains controversial. We audited our data over an 11-year period to assess the impact of AT.
Methods: This study included all patients who underwent curative resection for GBC from 2007 to 2017.
Preoperative clinical and contrasted-enhanced CT features to predict perineural invasion in gallbladder carcinoma: focus on clinical T3-4 stage.
Abdom Radiol (NY)
December 2024
Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Purpose: To investigate the utility of combining clinical and contrasted-enhanced tomography (CECT) parameters for the preoperative evaluation of perineural invasion (PNI) in gallbladder carcinoma (GBC).
Methods: A total of 134 patients with GBC (male/female, 52/82; age, 64.4 ± 9.
Graph convolution networks model identifies and quantifies gene and cancer specific transcriptome signatures of cancer driver events.
Comput Biol Med
December 2024
Gaffin Center for Neuro-Oncology, Sharett Institute for Oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel; The Wohl Institute for Translational Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel. Electronic address:
Background: The identification and drug targeting of cancer causing (driver) genetic alterations has seen immense improvement in recent years, with many new targeted therapies developed. However, identifying, prioritizing, and treating genetic alterations is insufficient for most cancer patients. Current clinical practices rely mainly on DNA level mutational analyses, which in many cases fail to identify treatable driver events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!